OWEN KATEY EINTERZ

SEC Form 4 insider trading activity

OWEN KATEY EINTERZ has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Sep 2, 2026.

On the most recent filing, OWEN KATEY EINTERZ is listed as Director at Adaptive Biotechnologies Corp. Inside the rolling window, OWEN KATEY EINTERZ reported no open-market purchases and 1 open-market sale totaling $250K in ADPT.

Companies traded

Other insiders at ADPT

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$250K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
ADPT
OWEN KATEY EINTERZ
Sale$250KAug 28SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has OWEN KATEY EINTERZ made?

OWEN KATEY EINTERZ has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.

Which companies does OWEN KATEY EINTERZ trade?

OWEN KATEY EINTERZ has filed SEC Form 4 disclosures for 1 company, including ADPT.

When was OWEN KATEY EINTERZ's most recent SEC Form 4 filing?

OWEN KATEY EINTERZ's most recent SEC Form 4 filing on Tracefour is dated Sep 2, 2026.

What is OWEN KATEY EINTERZ's total buy and sell value in the current window?

Inside the rolling retention window, OWEN KATEY EINTERZ bought $0 and sold $250K based on SEC Form 4 filings.

What was OWEN KATEY EINTERZ's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 9,615 ADPT shares on 2026-08-26, worth $250K, per SEC Form 4 filings.